Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover

We studied clinical performance of serum TRACP 5b and other bone turnover markers, including S‐CTX, U‐DPD, S‐PINP, S‐BALP, and S‐OC, for monitoring alendronate treatment. TRACP 5b had higher clinical sensitivity, area under the ROC curve, and signal‐to‐noise ratio than the other markers.

[1]  C. Minkin.  Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function , 1982, Calcified Tissue International.

[2]  M. Econs,et al.  Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). , 2004, Clinical chemistry.

[3]  Anders Isaksson,et al.  Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  R. Eastell,et al.  Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. , 2004, Bone.

[5]  E. Terpos,et al.  Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia , 2003, British journal of haematology.

[6]  D. Neustadt,et al.  Disease‐Specific Expression of Tartrate‐Resistant Acid Phosphatase Isoforms , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  J. Goldman,et al.  Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma , 2003, International journal of cancer.

[8]  H. Genant,et al.  Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. , 2003, Bone.

[9]  Yuh-Feng Lin,et al.  Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  H. Böttcher,et al.  Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients. , 2003, Anticancer research.

[11]  M. Koizumi,et al.  Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. , 2003, Anticancer research.

[12]  J. Goldman,et al.  Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin‐6 and β2‐microglobulin in multiple myeloma , 2003, European journal of haematology.

[13]  M. Koizumi,et al.  Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer , 2003, Breast cancer.

[14]  R. S. Seelan,et al.  Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[15]  F. De Conno,et al.  Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. , 2002, The International journal of biological markers.

[16]  T. Hentunen,et al.  Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[17]  H. Suominen,et al.  Serum Tartrate-Resistant Acid Phosphatase 5b, but not 5a, Correlates with Other Markers of Bone Turnover and Bone Mineral Density , 2002, Calcified Tissue International.

[18]  P. Lehner,et al.  Tartrate-resistant Acid Phosphatase (Acp 5): Identification in Diverse Human Tissues and Dendritic Cells , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  Jozef Van Beeumen,et al.  The Highly Exposed Loop Region in Mammalian Purple Acid Phosphatase Controls the Catalytic Activity , 2001, Chembiochem : a European journal of chemical biology.

[20]  L. Yam,et al.  Naphthol‐ASBI Phosphate as a Preferred Substrate for Tartrate‐Resistant Acid Phosphatase Isoform 5b , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  M. Seibel,et al.  Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. , 2001, Clinical chemistry.

[22]  S. Sun,et al.  Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. , 2001, Clinical chemistry.

[23]  J. Mönkkönen,et al.  Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. , 2000, Clinical chemistry.

[24]  H. Suominen,et al.  Tartrate‐Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  S. Rai,et al.  Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. , 2000, Clinical chemistry.

[26]  M. Karp,et al.  Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum. , 2000, Clinical chemistry.

[27]  G. Andersson,et al.  Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. , 1999, The Biochemical journal.

[28]  R. Eastell,et al.  Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological Variability , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  T. Hentunen,et al.  Tartrate‐resistant acid phosphatase from human bone: Purification and development of an immunoassay , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  P. Kannus,et al.  Estimation of various mechanical characteristics of human bones using dual energy X-ray absorptiometry: methodology and precision. , 1996, Bone.

[31]  H. Yaziji,et al.  Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. , 1995, American journal of clinical pathology.

[32]  B. Averill,et al.  Purification and properties of the native form of the purple acid phosphatase from bovine spleen. , 1993, Biochemistry.

[33]  S. Robins,et al.  Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. , 1988, Analytical biochemistry.

[34]  J. Stepan,et al.  Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[35]  R. Desnick,et al.  Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. , 1981, Clinical biochemistry.

[36]  C. Li,et al.  Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. , 1978, Clinical chemistry.